Resveratrol up-regulates ATP2A3 gene expression in breast cancer cell lines through epigenetic mechanisms

Izquierdo-Torres, Eduardo; Hernández‐Oliveras, Andrés; Meneses-Morales, Iván; Rodrı́guez, Gabriela; Fuentes-García, Gabriela; Zarain‐Herzberg, Ángel

doi:10.1016/j.biocel.2019.05.020

Cited by 55 publications

(30 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ATP2A3 gene plays a significant role in intracellular Ca 2+ management and normal cell death process, and transcriptional down-regulation of ATP2A3 has been identified in various cancers including breast cancer [95]. Furthermore, HDAC inhibitors enhanced the expression levels of ATP2A3 in breast cancer [94]. In another study, resveratrol combined with grape seed proanthocyanidins significantly decreased the DNMT and HDAC activity in breast cancer cell lines [96].…”

Section: Resveratrol Upregulates Atp2a3 Expressionmentioning

confidence: 94%

“…Available reports indicate that resveratrol inhibits different stages of cancer progression, such as proliferation and metastasis. A recent study found that resveratrol treatment enhanced the ATP2A3 expression significantly by increasing the H3 lysine 27 acetylation on the ATP2A3 gene promoter and decreased the activity of DNMT and the expression levels of methyl-DNA binding proteins MeCP2 and MBD2 [94]. The ATP2A3 gene plays a significant role in intracellular Ca 2+ management and normal cell death process, and transcriptional down-regulation of ATP2A3 has been identified in various cancers including breast cancer [95].…”

Section: Resveratrol Upregulates Atp2a3 Expressionmentioning

confidence: 99%

See 1 more Smart Citation

Flavonoids and Other Polyphenols Act as Epigenetic Modifiers in Breast Cancer

et al. 2020

View full text Add to dashboard Cite

Breast cancer is a common cancer that occurs due to different epigenetic alterations and genetic mutations. Various epidemiological studies have demonstrated an inverse correlation between breast cancer incidence and flavonoid intake. The anti-cancer action of flavonoids, a class of polyphenolic compounds that are present in plants, as secondary metabolites has been a major topic of research for many years. Our review analysis demonstrates that flavonoids exhibit anti-cancer activity against breast cancer occurring in different ethnic populations. Breast cancer subtype and menopausal status are the key factors in inducing the flavonoid’s anti-cancer action in breast cancer. The dose is another key factor, with research showing that approximately 10 mg/day of isoflavones is required to inhibit breast cancer occurrence. In addition, flavonoids also influence the epigenetic machinery in breast cancer, with research demonstrating that epigallocatechin, genistein, and resveratrol all inhibited DNA methyltransferase and altered chromatin modification in breast cancer. These flavonoids can induce the expression of different tumor suppressor genes that may contribute to decreasing breast cancer progression and metastasis. Additional studies are required to confirm the contribution of epigenetic modifications by flavonoids to breast cancer prevention.

show abstract

Section: Resveratrol Upregulates Atp2a3 Expressionmentioning

confidence: 94%

Section: Resveratrol Upregulates Atp2a3 Expressionmentioning

confidence: 99%

Flavonoids and Other Polyphenols Act as Epigenetic Modifiers in Breast Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, it has been shown to modulate a great variety of cellsignaling pathways and interact with numerous molecular targets (Harikumar and Aggarwal, 2008). Notably, it was demonstrated that resveratrol is an activator of type III HDAC (Kaeberlein et al, 2005) but, in certain tumor lines, RSV downregulates DNA methyltransferases (DNMT), inhibits HDACs type I or II, and activates HAT, impacting on epigenetic marks in different ways (Chatterjee et al, 2019;Hu et al, 2019;Izquierdo-Torres et al, 2019). RSV inhibits growth of T. gondii in vitro with an IC 50 of 54 µM after 24 h of treatment on extracellular tachyzoites (Chen et al, 2019).…”

Section: Hdac/kdac Inhibitorsmentioning

confidence: 99%

Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs

Angel

Vanagas

Ruiz

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Toxoplasma gondii is the causative agent of toxoplasmosis in animals and humans. This infection is transmitted to humans through oocysts released in the feces of the felines into the environment or by ingestion of undercooked meat. This implies that toxoplasmosis is a zoonotic disease and T. gondii is a foodborne pathogen. In addition, chronic toxoplasmosis in goats and sheep is the cause of recurrent abortions with economic losses in the sector. It is also a health problem in pets such as cats and dogs. Although there are therapies against this infection in its acute stage, they are not able to permanently eliminate the parasite and sometimes they are not well tolerated. To develop better, safer drugs, we need to elucidate key aspects of the biology of T. gondii. In this review, we will discuss the importance of the homologous recombination repair (HRR) pathway in the parasite's lytic cycle and how components of these processes can be potential molecular targets for new drug development programs. In that sense, the effect of different DNA damage agents or HHR inhibitors on the growth and replication of T. gondii will be described. Multitarget drugs that were either associated with other targets or were part of general screenings are included in the list, providing a thorough revision of the drugs that can be tested in other scenarios.

show abstract

“…Indeed, various inhibitors of SERCA such as thapsigargin, cyclopiazonic acid, and curcumin have been widely used as anticancer drugs in numerous cancers. Furthermore, short-chain fatty acids (e.g., butyrate, valerate, and caproate) and resveratrol have been shown to induce SERCA3 expression and inhibit cell survival in gastrointestinal carcinoma and breast cancer, respectively [63,71]. A curcumin analog F36 is an example of a SERCA inhibitor which has been shown to reduce the proliferation of colorectal cancer cells through inhibiting SERCA2 expression [72].…”

Section: Sercamentioning

confidence: 99%

Exploring the Therapeutic Potential of Membrane Transport Proteins: Focus on Cancer and Chemoresistance

Almasi

Hiani

2020

Cancers

View full text Add to dashboard Cite

Improving the therapeutic efficacy of conventional anticancer drugs represents the best hope for cancer treatment. However, the shortage of druggable targets and the increasing development of anticancer drug resistance remain significant problems. Recently, membrane transport proteins have emerged as novel therapeutic targets for cancer treatment. These proteins are essential for a plethora of cell functions ranging from cell homeostasis to clinical drug toxicity. Furthermore, their association with carcinogenesis and chemoresistance has opened new vistas for pharmacology-based cancer research. This review provides a comprehensive update of our current knowledge on the functional expression profile of membrane transport proteins in cancer and chemoresistant tumours that may form the basis for new cancer treatment strategies.

show abstract

Resveratrol up-regulates ATP2A3 gene expression in breast cancer cell lines through epigenetic mechanisms

Cited by 55 publications

References 51 publications

Flavonoids and Other Polyphenols Act as Epigenetic Modifiers in Breast Cancer

Flavonoids and Other Polyphenols Act as Epigenetic Modifiers in Breast Cancer

Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs

Exploring the Therapeutic Potential of Membrane Transport Proteins: Focus on Cancer and Chemoresistance

Contact Info

Product

Resources

About